Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Simian virus 40 (SV40) early promoter is a potent regulatory DNA sequence derived from the genome of the SV40 polyomavirus [4, 10]. It is structurally composed of three essential functional domains: an AT-rich TATA box that directs the site of transcription initiation, a 21-base pair (bp) repeat region containing six GC boxes that serve as binding sites for the Sp1 transcription factor, and a 72-bp tandem repeat region acting as a transcriptional enhancer [4, 5, 8]. In its native viral context, the promoter initiates the transcription of early genes, primarily the Large T and Small t antigens, which are vital for viral genome replication and the malignant transformation of host cells [5, 10, 21]. Because of its high constitutive activity in a broad range of mammalian cell types, it is extensively utilized as a tool in biotechnology to drive the high-level expression of recombinant proteins, selectable markers, and reporter genes in mammalian expression vectors [8, 19]. While primarily viewed as a genetic tool, it is also a site for pharmacological intervention; drugs such as mithramycin A and trabectedin target the GC-rich sequences within the promoter to inhibit transcription factor recruitment and suppress gene expression [16, 17]. However, the inclusion of SV40-derived elements in therapeutic products raises safety concerns regarding their potential to drive the expression of oncogenes or inadvertently promote tumorigenesis through genomic integration [12, 22].
Inhibition of transcription through competitive binding to GC-rich DNA motifs within the promoter region, which displaces essential transcription factors like Sp1 and prevents the assembly of the RNA polymerase II pre-initiation complex
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Simian virus 40 early promoter (SV40 early promoter) (SV40 early promoter).